Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hormone Receptor-Positive Breast Cancer: early-phase trial registry
19 of 24 indexed Hormone Receptor-Positive Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #686 of 28,707 conditions by registered trial count.
24 US clinical trials · 19 currently recruiting · #686 of 28,707 conditions by registered trial count
Hormone Receptor-Positive Breast Cancer: 24 US clinical trials tracked, 19 recruiting.
Hormone Receptor-Positive Breast Cancer is the subject of 24 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Exelixis, running 2 of these trials.
Enrollment posture brief
Registry condition hormone-receptor-positive-breast-cancer
OPEN 19 | RECR 79% | LATE 1 | EARLY 21 | RANK #686 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Kaposi Sarcoma (79% recruiting · 14 trials)
Hormone Receptor-Positive Breast Cancer lists 19 open slots (79% of 24 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hormone Receptor-Positive Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hormone Receptor-Positive Breast Cancer is recruiting above its size-band peers.
19 of 24 indexed trials (79.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hormone Receptor-Positive Breast Cancer trials is spread across many organizations.
Exelixis accounts for 2 of 24 trials (8.3%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Hormone Receptor-Positive Breast Cancer enrolment sits around 120 participants.
Median target enrolment is 120 among the 24 trials that report a genuine target (sentinel values excluded). 11 of those (45.8%) plan for fewer than 100 participants.
-
Hormone Receptor-Positive Breast Cancer research is mostly interventional.
22 interventional and 2 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
24 total, page 1 of 1
Study of XB010 in Subjects With Solid Tumors
Exelixis
NCT06545331
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Dana-Farber Cancer Institute
NCT04569747
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeiGene
NCT06120283
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci
NCT07222215
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeiGene
NCT06257264
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Oana Danciu
NCT05467891
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Baylor Breast Care Center
NCT05020860
Study of Screening Brain MRIs in Stage IV Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05115474
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
BeOne Medicines
NCT06756932
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
Mayo Clinic
NCT06388122
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
NCT05573126
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
Reshma L. Mahtani, D.O.
NCT06263543
VS-6766+Abema+Fulv in Met HR+/HER- BC
Adrienne G. Waks
NCT05608252
A Study of Revaree Plus in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT07042581
ETHAN - ET for Male BC
Jose Pablo Leone
NCT05501704
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Rutgers, The State University of New Jersey
NCT06518837
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06678269
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Calibr, a division of Scripps Research
NCT06878248
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
NCT05524584
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Daiichi Sankyo Co.
NCT03401385
TH1902 in Patients With Advanced Solid Tumors
Theratechnologies
NCT04706962
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT05064085
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Exelixis
NCT04925284
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT01177397
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 8 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hormone Receptor-Positive Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hormone Receptor-Positive Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hormone Receptor-Positive Breast Cancer page
24 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 19 Hormone Receptor-Positive Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Exelixis sponsors the most Hormone Receptor-Positive Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Exelixis's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hormone Receptor-Positive Breast Cancer condition card totals 24 registered trials; most-linked intervention Fulvestrant; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.